ホーム > 市場調査レポート > 医薬品

市場調査レポート

商品コード

1085757

進行性核上性麻痺治療の世界市場：薬剤タイプ別、流通チャネル別、地域別 - 規模、シェア、展望、機会分析（2022年～2028年）

Progressive Supranuclear Palsy Treatment Market, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日: 2022年05月12日 | 発行: Coherent Market Insights

| ページ情報: 英文 195 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,500 705,420円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Multi User License)

USD 7,000 1,097,320円

レポートPDFを7名までにてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は7回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise User License)

USD 10,000 1,567,600円

レポートPDFを同一企業およびその子会社のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
目次

概要

サンプル依頼リストに入れる

進行性核上性麻痺治療市場の成長を牽引するのは、進行性核上性麻痺（PSP）の発症率の上昇であると予想されています。例えば、National Institute of Neurological Disorders and Strokeが2020年7月に発表した論文によると、世界で10万人に3～6人程度が進行性核上性麻痺であり、米国では約2万人が進行性核上性麻痺を患っていると報告されています。

しかし、進行性核上性麻痺の特定や診断が不十分であることが、市場成長の妨げになると予想されます。

当レポートでは、世界の進行性核上性麻痺治療市場について調査分析し、市場促進要因と抑制要因、市場機会、COVID-19の影響、薬剤タイプ・流通チャネル・地域別の市場分析、競合情勢などを提供しています。

ヒートマップ分析
市場シェア分析
- AbbVie Inc.
- Acorda Therapeutics Inc.
- Biogen Inc.
- Bristol-Myers Squibb Co.
- Merck & Co. Inc.
- UCB Biopharma
- AlzProtect
- Asceneuron Therapeutics
- TauRx Pharmaceuticals
- GlaxoSmithKline PLC
- Novartis AG
- Teva Pharmaceutical Industries Ltd
アナリストの見解

第9章セクション

Product Code: CMI4277

Progressive supranuclear palsy (PSP) is a neurodegenerative disease alike Parkinson's disease. The disease results from damage to nerve cells in the brain. One of the common symptomof the disease include inability to aim and move the eyes properly, where individuals may experience as blurring of vision. It is a rare brain disorder that affects body movement, control of walking i.e. gait and balance, speech, swallowing, vision, mood and behavior, and thinking.

Market Dynamics

Rising incidence of progressive supranuclear palsy (PSP) is expected to drive progressive supranuclear palsy treatment market growth. For instance, according to the National Institute of Neurological Disorders and Stroke, an article published in July 2020, reports that about 3-6 in every 100,000 people have progressive supranuclear palsy worldwide, and around 20,000 U.S. populace are suffering from progressive supranuclear palsy.

However, lack of identification or diagnosis of progressive supranuclear palsy are expected to hinder the market growth. For instance, according to the National Institute of Neurological Disorders and Stroke, an article published in July 2020, states that currently there are no specific laboratory tests or imaging approaches are definitively diagnose progressive supranuclear palsy.

Key features of the study:

This report provides in-depth analysis of the global progressive supranuclear palsy treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global progressive supranuclear palsy treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are AbbVie Inc., Acorda Therapeutics Inc., Biogen Inc., Bristol-Myers Squibb Co., Merck & Co. Inc., UCB Biopharma, AlzProtect, Asceneuron Therapeutics, TauRx Pharmaceuticals, GlaxoSmithKline PLC, Novartis AG, and Teva Pharmaceutical Industries Ltd. among others
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global progressive supranuclear palsy treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global progressive supranuclear palsy treatment market.

Detailed Segmentation:

Global Progressive Supranuclear Palsy Treatment Market, By Drug Type:
- Dopamine
- Anticholinergic Agents
- Tricyclic Antidepressants
- Others
Global Progressive Supranuclear Palsy Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Progressive Supranuclear Palsy Treatment Market, By Region:
- North America
  - By Drug Type:
  - Dopamine
  - Anticholinergic Agents
  - Tricyclic Antidepressants
  - Others
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country:
  - U.S.
  - Canada
- Latin America
  - By Drug Type:
  - Dopamine
  - Anticholinergic Agents
  - Tricyclic Antidepressants
  - Others
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Europe
  - By Drug Type:
  - Dopamine
  - Anticholinergic Agents
  - Tricyclic Antidepressants
  - Others
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country:
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
- Asia Pacific
  - By Drug Type:
  - Dopamine
  - Anticholinergic Agents
  - Tricyclic Antidepressants
  - Others
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country:
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - By Drug Type:
  - Dopamine
  - Anticholinergic Agents
  - Tricyclic Antidepressants
  - Others
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country:
  - GCC
  - Israel
  - Rest of Middle East
- Africa
  - By Drug Type:
  - Dopamine
  - Anticholinergic Agents
  - Tricyclic Antidepressants
  - Others
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
- AbbVie Inc.*
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Highlights
  - Market Strategies
- Acorda Therapeutics Inc.
- Biogen Inc.
- Bristol-Myers Squibb Co.
- Merck & Co. Inc.
- UCB Biopharma
- AlzProtect
- Asceneuron Therapeutics
- TauRx Pharmaceuticals
- GlaxoSmithKline PLC
- Novartis AG
- Teva Pharmaceutical Industries Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Pipeline Analysis
Reimbursement Scenario
Epidemiology
Pest Analysis
Regulatory Scenario
New Product Launches
Collaborations and Agreements
Market Trends

4. Global Progressive Supranuclear Palsy Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Market Scenario
Impact of COVID-19 Market on the Progressive Supranuclear Palsy Treatment Products

5. Global Progressive Supranuclear Palsy Treatment Market, By Drug Type, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Dopamine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Anticholinergic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Tricyclic Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global Progressive Supranuclear Palsy Treatment Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global Progressive Supranuclear Palsy Treatment Market, By Region, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
North America
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- U.S.
- Canada
Latin America
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
Africa
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Mn)
- South Africa
- Central Africa
- North Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Acorda Therapeutics Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Biogen Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bristol-Myers Squibb Co.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Merck & Co. Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- UCB Biopharma
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AlzProtect
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Asceneuron Therapeutics
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- TauRx Pharmaceuticals
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline PLC
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Analyst Views

9. Section

References
Research Methodology
About us and Sales Contact

ライセンス / 価格

PDF (Single User License)

USD 4,500 705,420円

PDF (Multi User License)

USD 7,000 1,097,320円

PDF (Enterprise User License)

USD 10,000 1,567,600円

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

お電話でのお問い合わせ

044-952-0102

( 土日・祝日を除く )

進行性核上性麻痺

進行性核上性麻痺治療の世界市場：薬剤タイプ別、流通チャネル別、地域別 - 規模、シェア、展望、機会分析（2022年～2028年）

Progressive Supranuclear Palsy Treatment Market, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章調査目的・前提条件

第2章市場の範囲

第3章市場力学・規制・動向分析

第4章世界の進行性核上性麻痺治療市場：COVID-19流行の影響

第5章世界の進行性核上性麻痺治療市場：薬剤タイプ別（2017年～2028年）

第6章世界の進行性核上性麻痺治療市場：流通チャネル別（2017年～2028年）

第7章世界の進行性核上性麻痺治療市場：地域別（2017年～2028年）

第8章競合情勢

第9章セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Progressive Supranuclear Palsy Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

5. Global Progressive Supranuclear Palsy Treatment Market, By Drug Type, 2017 - 2028, (US$ Mn)

6. Global Progressive Supranuclear Palsy Treatment Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

7. Global Progressive Supranuclear Palsy Treatment Market, By Region, 2017 - 2028, (US$ Mn)

8. Competitive Landscape

9. Section

進行性核上性麻痺治療の世界市場：薬剤タイプ別、流通チャネル別、地域別 - 規模、シェア、展望、機会分析（2022年～2028年）

Progressive Supranuclear Palsy Treatment Market, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章 調査目的・前提条件

第2章 市場の範囲

第3章 市場力学・規制・動向分析

第4章 世界の進行性核上性麻痺治療市場：COVID-19流行の影響

第5章 世界の進行性核上性麻痺治療市場：薬剤タイプ別（2017年～2028年）

第6章 世界の進行性核上性麻痺治療市場：流通チャネル別（2017年～2028年）

第7章 世界の進行性核上性麻痺治療市場：地域別（2017年～2028年）

第8章 競合情勢

第9章 セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Progressive Supranuclear Palsy Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

5. Global Progressive Supranuclear Palsy Treatment Market, By Drug Type, 2017 - 2028, (US$ Mn)

6. Global Progressive Supranuclear Palsy Treatment Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

7. Global Progressive Supranuclear Palsy Treatment Market, By Region, 2017 - 2028, (US$ Mn)

8. Competitive Landscape

9. Section

第1章調査目的・前提条件

第2章市場の範囲

第3章市場力学・規制・動向分析

第4章世界の進行性核上性麻痺治療市場：COVID-19流行の影響

第5章世界の進行性核上性麻痺治療市場：薬剤タイプ別（2017年～2028年）

第6章世界の進行性核上性麻痺治療市場：流通チャネル別（2017年～2028年）

第7章世界の進行性核上性麻痺治療市場：地域別（2017年～2028年）

第8章競合情勢

第9章セクション